Accepted author's manuscript. Published in final edited form as: American Journal of Hospice and Palliative Medicine 2022 (in press). Publisher DOI: <u>10.1177/10499091221130758</u>

Prescription Trends in Hospice Care: A Longitudinal Retrospective and Descriptive Medication Analysis

Ursina Wernli ^{1,2}, Désirée Hischier ³, Christoph R. Meier ³, Sibylle Jean-Petit-Matile ⁴, Alice Panchaud ⁵, Andrea Kobleder ⁶ and Carla Meyer-Massetti ^{1,3}

¹ Clinical Pharmacology and Toxicology, Inselspital University Hospital Bern, Bern, Switzerland

² Graduate School for Health Sciences, University of Bern, Bern, Switzerland

³ Clinical Pharmacy and Pharmacoepidemiology, University of Basel, Basel, Switzerland

⁴ Hospice of Central Switzerland, Lucerne, Switzerland

⁵ Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland

⁶ Institute of Applied Nursing Science, Eastern Switzerland University of Applied SciencesOST, St Gallen, Switzerland

Ursina Wernli, Inselspital University Hospital Bern, Freiburgstrasse 18, Bern 3010, Switzerland. Email: ursina.wernli@students.unibe.ch

Background: In hospice and palliative care, drug therapy is essential for symptom control. However, drug regimens are complex and prone to drug-related problems. Drug regimens must be simplified to improve quality of life and reduce risks associated with drug-related problems, particularly at end-oflife. To support clinical guidance towards a safe and effective drug therapy in hospice care, it is important to understand prescription trends.

6 Objectives: To explore prescription trends and describe changes to drug regimens in inpatient hospice
7 care.

8 Design: We performed a retrospective longitudinal and descriptive analysis of prescriptions for regular

9 and as-needed (PRN) medication at three timepoints in deceased patients of one Swiss hospice.

10 Setting/subjects: Prescription records of all patients (\geq 18 years) with an inpatient stay of three days 11 and longer (admission and time of death in 2020) were considered eligible for inclusion.

Results: Prescription records of 58 inpatients (average age 71.7 ± 12.8 [37-95] years) were analyzed.
The medication analysis showed that polypharmacy prevalence decreased from 74.1% at admission to
13.8% on the day of death. For regular medication, overall numbers of prescriptions decreased over the
patient stay while PRN medication decreased after the first consultation by the attending physician and
increased slightly towards death.

17 Conclusions: Prescription records at admission revealed high initial rates of polypharmacy that were 18 reduced steadily until time of death. These findings emphasize the importance of deprescribing at end-19 of-life and suggest pursuing further research on the contribution of clinical guidance towards optimizing 20 drug therapy and deprescribing in inpatient hospice care.

22 Introduction

23 In palliative care, symptom control is essential, particularly at end-of-life. Drug therapy is focused on 24 decreasing patients' symptom burden and improving their quality of life.[1, 2] However, end-of-life 25 medication must balance complex factors, which characterize the pathophysiological changes that are 26 associated with the last phase of life. Drug-related problems (DRPs) may arise from the patients' general 27 vulnerability, their comorbidities, and their high prevalence of polypharmacy (\geq 5 drugs administered 28 regularly daily).[3-6] On average, palliative care patients receive 7.1-7.8 drugs daily.[7, 8] This level of 29 polypharmacy increases the risks not only of drug-drug interactions and drug-disease interactions, but 30 also of medication errors.[9, 10]

31 A study conducted in Germany in 2021 in patients of a palliative care unit demonstrated DRPs' impact 32 on symptom progression: With increasing symptom control requirements and medication regimens 33 becoming more complex, DRPs increased as well.[11] At end-of-life it is necessary to simplify drug 34 regimens in order to optimize quality of life and reduce risks associated with DRPs.[12, 13] It is also 35 necessary to balance desirable increases in prescribed drugs used for symptom control and avoid 36 polypharmacy, especially in prescriptions with a focus on life extension and primary prevention.[14-16] 37 Deprescribing involves weighing each drug's known or potential harm against its expected benefits.[17] 38 This process is particularly relevant in hospice care where therapeutic goals change drastically with the 39 decision to pursue non-curative treatment in favor of symptom management and quality of life.[18] 40 These goals must constantly be assessed and adapted as necessary. Patients' individual goals as well as 41 patients' and their families' requirements and needs must be considered. Thus, the discontinuation of 42 medication can vary greatly over time.[19]

The problem of complex drug regimens in palliative care has been investigated and described in several studies.[2, 7, 20, 21] However, studies investigating whether drug regimens in hospice care are associated with similar levels of complexity remain low in number. Most of the available studies only assess medication cross-sectionally at one timepoint only, usually on the day of death. In order to gauge

- 47 what contributions could support clinical guidance towards a safe and effective drug therapy in hospice
- 48 care, it is important to investigate prescription trends in this setting.
- 49 This study aims to analyze prescription trends and describe changes to drug regimens from hospice
- 50 admission to death.
- 51

52 Methods

53 The retrospective longitudinal and descriptive analysis of prescriptions was performed in the Hospice of 54 Central Switzerland in the Canton of Lucerne, a 12-bed institution that provides specialized palliative 55 care (in Switzerland, provision of specialized palliative care in a hospice is considered hospice care).[22] 56 One attending physician is responsible for the medication; prescriptions are written and collected on 57 structured paper-based standard forms ("prescription sheets"). Data of patients and prescription sheets 58 were anonymized using numeric coding. In compliance with Swiss data protection rights, the key for 59 these codes was accessible only to the hospice administration team. Eligibility criteria for patient 60 enrollment are displayed in Table 1.

61 Table 1: Eligibility criteria for patient enrollment

Inclusion criteria	Exclusion criteria
• \geq 18 years old with inpatient stay \geq 3 da	 • outpatients or inpatient stay < 3 days
• admission to the hospice in 2020	discharge to the home care setting c hospital
• time of death in the hospice in 2020	 explicitly documented restriction fror use of patient-specific data

62


63 In the study hospice, patients' baseline data (gender, age at admission, diagnoses, duration of stay) are 64 collected for all patients upon admission. Within three days, the attending physician reviews their 65 medications and makes the first changes to their drug regimens. All patients with an inpatient stay of 66 three or more days that were admitted to the hospice in 2020 and died in the hospice in the same year 67 were considered eligible for inclusion. To determine the most relevant diagnosis that led to hospice 68 admission, we extracted the five diagnoses of each patient based on ICD-10 classifications we 69 considered the most relevant. We extracted medication-related information from the prescription 70 sheets at three timepoints: first day of admission (t_1) ; day 3 post-admission (after first consultation and 71 changes to medication by attending physician) (t_2); and day of death (t_3). Data on regular medication 72 and as-needed medication (PRN) were collected separately at the same three timepoints. Medication 73 data (i.e., active substance, brand name, dosage, formulation, dosage interval, route of application, off14 label use) was extracted for the medication analysis and collected in an Excel® table. Anatomical 15 Therapeutic Chemical (ATC) codes were used to categorize the drugs according to the fourteen main 16 anatomical or pharmacological groups (first level).[23] The route of application was classified according 17 to the WHO abbreviations.[23] Descriptive analysis was performed for the baseline data to allow 17 calculation of the relevant means and standard deviations. To compare the number of medications 17 across the three timepoints, we performed a one-way ANOVA test followed by a post hoc Tukey HSD 18 test. Statistical analyses were performed in R studio (*R version 3.6.3*).


81

Ethical approval for this study was obtained from the Ethics Committee of Northwestern and Central
Switzerland (EKNZ, ID 2021-00411). Authors followed the STROBE Statement for cross-sectional
studies.[24]

85 Results

86 Fifty-eight patients met the study's inclusion criteria. Their medical records were assessed for data





00

Figure 1: Flow chart of patient recruitment according to inclusion and exclusion criteria

97

98 Patient baseline data

99 Extracted baseline patient data are shown in Table 2 (for detailed patients' baseline data see

100 supplementary material SA1). The median duration of stay (range) was 13.5 (3-146) days. However, the

- 101 range was very heterogeneous: the majority of patients stayed between 21 and 50 days (n=16). Thirteen
- 102 patients stayed three to five days, and another 13 stayed six to ten days. Eight patients stayed 11 to 20

103 days; and five 51 to 100 days. Three patients stayed much longer, 101, 112, and 146 days, respectively.

- 104 The most common hospice-relevant diagnoses (ICD-10) were neoplasms in 51/58 patients (88.0%).
- 105 Table 2: Patient baseline data

Baseline Patient Characteristics						
patients total N (%)	58 (100%)					
gender	n (%)					
female	26 (45%)					
male	32 (55%)					
age (years)	n (%)					
mean ± SD (range)	71.7 ±12.80 (37-95)					
≥30 to ≤39	2 (3.4%)					
≥40 to ≤49	2 (3.4%)					
≥50 to ≤59	3 (5.2%)					
≥60 to ≤69	17 (29.3%)					
≥70 to ≤79	16 (27.6%)					
≥80 to ≤89	14 (24.1%)					
≥90	4 (6.9%)					
duration of stay	(in days)					
median (range)	13.5 (3-146)					
most common hospice-relevant diagnosis (ICD-10)	n (%)					
Neoplasms	51 (88.0%)					
Amyotrophic lateral sclerosis	1 (1.7%)					
Asthenia	1 (1.7%)					
Chronic kidney disease	1 (1.7%)					
Chronic obstructive lung disease	1 (1.7%)					
Creutzfeldt-Jakob disease	1 (1.7%)					
Pelvic fracture	1 (1.7%)					
Severe cachexia	1 (1.7%)					
patients with polypharmacy [*] drug regimen	n (%)					
t ₁	43 (74.1%)					
t ₂	20 (34.5%)					
t ₃	8 (13.8%)					
t_1 : admission, t_2 : first change to medication on day t	hree, t_3 : day of death, SD: standard deviation,					

t₁: admission, t₂: first change to medication on day three, t₃: day of death, SD: standard deviation, *regular medication \geq 5 drugs per day

106

107 Drug regimens

 $108 \qquad \text{The total number of prescribed drugs decreased from t_1 to t_3 for regular medications; PRN medications}$

109 initially decreased, then increased again near the time of death (see *Table 3*). The mean of prescribed

110 drugs prescribed per patient varied significantly (ANOVA; F(2, 171) =[29.17], p<0.001) between the

111 measurement points for regular medication with significant decrease between t_1 and t_2 (Post hoc Tukey; 112 p<0.001), and between t_1 and t_3 (Post hoc Tukey; p<0.001). No significant difference was observed 113 between t_2 and t_3 (Post hoc Tukey; p=0.08). For PRN medication, the average number of prescribed 114 drugs also differed significantly (ANOVA; F(2, 171) = [5.57], p=0.005). The decrease in the mean number 115 of PRN drugs per patient was significant between t_1 and t_2 (Post hoc Tukey test: p=0.004) but fell slightly 116 short of significance between t_1 and t_3 (Post hoc Tukey test: p = 0.052). The mean number of prescribed 117 PRN medications per patient increased slightly between t_2 and t_3 (Post hoc Tukey test: p = 0.658), 118 although not significantly.

The number of patients with no regular medications prescribed increased slightly after the first change of medication by the hospice physician (t_2) and decreased again on the day of death (t_3). Regarding patients receiving no PRN medications, the number first decreased rapidly from six (t_1) to one (t_2), increasing to two on the day of death (t_3). The number of patients with a polypharmacy drug regimen (\geq 5 drugs in regular drug regimen) was highest at admission (t_1 : n=43) and was reduced by more than half between t_1 and t_2 (n=20), and between t_2 and t_3 (n=8) (see *Table 3*).

The number of drugs prescribed off-label (defined by European Medicines Agency as 'Use of a medicine for an unapproved indication or in an unapproved age group, dosage, or route of administration'[25]) is larger in PRN medications compared to regular medications. For both regular and PRN medications, the percentage of drugs administered for off-label uses increased towards death. Of a total of 436 drugs prescribed at time of death, 105 (24.1%) were used off-label; at admission only 30/794 drugs prescribed (3.8%) were used off-label (see *Table 3*).

- 131
- 132 Table 3: Summary of prescriptions and active substances at each point in time

Regimen	Time	Mean number of prescribed drugs per patient (range)	Number of patients with polypharmacy regimen (n=)	Number of patients without prescription (n=)	Total number of prescriptions (N=)	Number of different prescribed drugs ^a (n=)	Number of different prescribed substances ^b (n=)	Number of off- label prescriptions ^c
Regular	t1	7.0 (0-19)	43 (74.1%)	4	406	247	131	6/405 (1.5%)
	t2	3.8 (0-13)	20 (34.5%)	8	220	138	72	7/215 (3.3%)
	t3	2.5 (0-11)	8 (13.8%)	6	143	97	44	18/143 (12.6%)
PRN ⁺	t1	6.7 (0-19)	n/a	6	390	155	82	24/389 (6.2%)
	t2	4.4 (0-20)	n/a	1	257	72	41	63/257 (24.5%)
	t3	5.1 (0-20)	n/a	2	293	74	46	87/293 (29.7%)


^anumber of all drugs prescribed at specific point in time (t_x), where one drug could contain multiple substances ^bnumber of all substances prescribed at specific point in time (t_x), where one substance could be prescribed and administered in different formulations (e.g., morphine drops for oral intake and morphine solution for subcutaneous administration) ^cprescriptions with unknown off-label status were excluded [†]PRN: pro re nata medication (as-needed medication)

133

- 134 Over the whole study period, the five active ingredients most frequently prescribed for regular use were
- 135 morphine (n=60), fentanyl (n=48), sodium picosulfate (n=34), pantoprazole (n=26), and dexamethasone
- 136 (n=23) (n=number of prescriptions). For PRN medications, morphine (n=152), lorazepam (n=96),
- haloperidol (n=95), midazolam (n=85), and metoclopramide (n=31) were most frequently prescribed.

139 ATC codes and routes of administration

140 The drugs were categorized according to their ATC codes (see figure 2) and routes of administration



141 (see figure 3).



Figure 2 shows the counts of each ATC code for the regular (A) and PRN medication (C). **ATC Codes: A**: Alimentary tract and metabolism, **B**: Blood and blood forming organs, **C**: Cardiovascular system, **D**: Dermatologicals, **G**: Genito urinary system and sex hormones, **H**: Systemic hormonal preparations, excluding sex hormones and insulins, **J**: Antiinfectives for systemic use, **L**: Antineoplastic and immunomodulating agents, **M**: Musculo-skeletal system, **N**: Nervous system, **P**: Antiparasitic products, insecticides and repellents, **R**: Respiratory system, **S**: Sensory organs, **V**: Various

142

143 At admission, the majority of drugs prescribed for regular use belonged to the ATC code category

144 *Nervous system* (t₁: 154/406, 37.9%), followed by *Alimentary tract and metabolism* (t₁: 112/406, 27.6%),

145 Cardiovascular system (t₁: 28/406, 6.9%), and Systemic hormonal preparations (t₁: 28/406, 6.9%).

- 146 Nearing death, the proportion of prescriptions within the category *Nervous system* increased (t₂:
- 147 107/220, 48.6%, t₃: 87/143, 60.1%), while prescriptions for the categories Alimentary tract and
- 148 metabolism (t₂: 58/220, 26.4%, t₃: 35/143, 22.9%) and Cardiovascular system (t₂: 14/220, 6.4%, t₃:
- 149 4/143, 2.8%) decreased slightly. At admission, the majority of PRN medications prescribed were in the

category *Nervous system* (t_1 : 207/390, 53.1%). That proportion increased drastically after three days (t_2 : 207/257, 80.5%) and thereafter only decreased slightly on the day of death (t_3 : 230/293, 78.5%). As for regular medication regimens, the second most common PRN category was *Alimentary tract and metabolism* (t_1 : 137/390, 35.1%). In this case, though, the proportion of prescriptions decreased on t_2 (34/257, 13.2%), then increased slightly on the day of death (t_3 : 46/293, 15.7%).




Figure 3: Routes of administration at each timepoint

Figure 3 shows the distribution of the identified routes of administration for the regular (A) and PRN (B) medication.

At t_1 and t_2 , most prescribed drugs (both regular and PRN) were administered orally (i.e., buccal, oral, sublingual). On the day of death (t_3), the number of orally (n=58) and parenterally (i.e., intramuscularly, intrathecally, intravenously, subcutaneously; n=64) administered drugs was almost identical within the regular drug regimen, indicating an overall increase in the use of the parenteral route. For PRN drugs, the number administered parenterally increased steadily (t_1 : n=61, t_2 : n=111, t_3 : n=152), while the number of orally administered drugs decreased (t_1 : n=287, t_2 : n=186, t_3 : n=126). Topically administered regular medications decreased at both t_2 and t_3 (t_1 : 39, n=, t_2 : n=15, t_3 : n=10). For PRN medications, the number administrated topically first decreased sharply, then remained stable between t₂ and t₃ (t₁:
n=10, t₂: n=1, t₃: n=1). Few regular medications were administered nasally (t₁: n=3, t₂: n=0, t₃: n=0).
Among PRN prescriptions, nasal application first decreased (t₁: n=11, t₂: n=4), then increased again
nearing death (t₃: n=5). Likewise, for both regular and PRN medications, the vaginal administration route
was used only marginally (regular medication: t₁: n=0, t₂: n=0, t₃: n=1, PRN: t₁: n=0, t₂: n=0, t₃: n=0).

167 Discussion

168 Our medication analysis revealed the complexity of drug regimens in hospice patients during the course 169 from admission to time of death, making the drug regimens especially prone to DRPs.[4] Among these 170 DRPs, occurring adverse drug reactions can easily be mistaken for symptoms that are common in 171 hospice and palliative care (e.g., mouth dryness, vertigo, fatigue). At admission, the included patients 172 were receiving an average of seven prescribed drugs for regular use. These findings are consistent with 173 a 2019 US retrospective cohort study that found a mean of 7.1 prescribed medications on discharge to 174 hospice care [8] and a 2014 European cross-sectional study that reported an average of 7.8 medications 175 in palliative care patients [7].

At end of life, significant medication burden is placed on patients.[16] However, polypharmacy prevalence was reduced consistently over the three measurement points (from 74.1% of patients at admission to 13.8% on day of death). This dramatic decrease in number of prescribed drugs between admission and time of death exemplifies the shift from disease-focused acute care to hospice care, with strong prioritization of comfort and symptom management. Further, findings indicate the relevance of deprescribing in hospice care, while maintaining optimal symptom control.

Structured approaches to balance out factors of undertreatment and overtreatment are growing, especially after studies in certain medical disciplines investigating adverse effects of polypharmacy on survival failed to show this effect.[26, 27] However, in hospice care representing end-of-life care, polypharmacy is still considered a valid indicator to assess quality of drug regimens. It is essential to find a good balance between prescribed medications with a benefit on quality of life for appropriate 187 symptom management and to reduce the medication burden in patients.[16] This is highly desirable in 188 hospice care, where patients are highly vulnerable to issues that could reduce their quality of life even 189 for a short time.[4, 28]

190 A 2015 multicenter, parallel-group, unblinded, pragmatic clinical trial on discontinuation of statin 191 therapy in patients with life-limiting illness suggested that discontinuing statins is safe, associated with 192 improved quality of life, and a decrease in total number of prescribed medications. The 60-days 193 mortality in patients with discontinued statin therapy was not significantly different compared to 194 patients with continued therapy (23.8% vs. 20.3%, 90% CI -3.5% to 10.5%, p=0.36).[29] Time to benefit 195 of statin in patients between 50 and 75 years is suspected to be approximately 1.5 to 3.0 years.[30] 196 Assuming a life expectancy of 6 months in hospice care, the effect of statin therapy is questionable. At 197 admission, only one patient received a statin which was discontinued after t_2 . This shows that 198 deprescribing of statin therapy is already applied in clinical settings preceding hospice admission. 199 However, at admission, pantoprazole was prescribed in 26 patients. On the day of death, it was only 200 prescribed in two patients. Timely medication review after admission to hospice seems an important 201 step to critically assess clinical benefits and appropriateness of prescribed medications, carefully 202 considering clinical situations as well as patients' and families conceptions and wishes, and to reduce 203 polypharmacy in the last phase of life, as shown in other settings.[31, 32]

204 The shift to comfort care and deprescribing raises the issue of assessing the appropriateness of drug 205 therapy in hospice care. Medication appropriateness should be carefully considered. However, 206 particularly in hospice care, assessments to identify potentially inappropriate medications are 207 challenging due to the high rates of comorbidities, rapid changes in manifestation of symptoms, and 208 uncertainty regarding life expectancy. Large, controlled intervention studies are avoided due to 209 patients' high frailty. Hence, only few guidelines are available to assess the appropriateness of 210 medications in end-of-life care settings (e.g., STOPP Frail criteria, OncPal).[33, 34] We observed a high 211 prevalence of medications for managing and treating comorbidities that are not directly associated with 212 the main diagnosis responsible for hospice care. Other studies have previously discussed this issue.[16,

213 18, 21] Complex and frequently changing drug therapy regimens, as identified in the medication
214 analysis, require thorough and regular assessment (e.g., medication review) and interprofessional
215 exchange.[28, 35, 36]

216 A high rate of off-label prescriptions was identified. This finding reflects the increasing need for 217 alternative routes of drug administration to manage symptoms at end-of-life. The most common shift 218 pertaining to the routes of administration concerned orally administered drugs shifting towards 219 parenteral use (mainly for PRN medication but also for regular medication). This finding is in accordance 220 with the preference of alternative routes of administration in hospice care. [21, 37, 38] Subcutaneous 221 drug administration offers a minimal invasive alternative when oral intake of drugs is severely limited 222 [39, 40]. This complies with the comfort-oriented approach of hospice care. Among the most frequently 223 prescribed drugs for regular and PRN use, the findings are comparable to the findings of a 2015 study 224 by Masman et al. revealing morphine, midazolam, and haloperidol as the most frequently prescribed 225 drugs during end-of-life care in a palliative care center.[2]

Even in small settings of hospice care where the variety of prescriptions is limited, support and guidance towards a safe and effective drug therapy is important, especially in end-of-life care patients with complex regimens and with strong considerations for maximizing quality of life.

229 Strengths and limitations

230 This is the first study that performed a longitudinal retrospective and descriptive medication analysis to 231 reveal the complexity of medication regimens in hospice care. In this study, retrospective data collection 232 and analysis of anonymized patient prescription records reduced the risk of selection bias. However, as 233 the study was performed in a single institution, the medication analyses are only representative for one 234 single institution and not necessarily nationwide. Only one physician is responsible for changes in drug 235 regimens. Variability among prescribing physicians and deprescribing preferences are not well 236 represented in this medication analysis. Nevertheless, characteristics of the medication regimens and 237 aspects of medication safety identified here are consistent with those revealed in other studies. [2, 7,

8, 20, 21] Both the complexity of patients' drug regimens observed at admission and the progression of
their medication therapies support the general assumption in palliative care that regular medications
decrease steadily towards death, while the need for PRN medications increases.

241 Conclusion

242 This retrospective longitudinal and descriptive medication analysis provides an overview of hospice 243 patients' medication prescriptions and their changes over time. The findings help to understand 244 prescription trends and highlight important aspects of medication safety in inpatient hospice care, such 245 as high initial rates of polypharmacy at hospice admission which can compromise medication safety and 246 quality of life, especially in highly frail patients. The findings emphasize the importance of deprescribing 247 at end-of-life and the need for timely medication review after admission. Beneficial effects of 248 deprescribing on polypharmacy and on the quality of life, considering time to benefit, should be 249 assessed in patients with a limited life expectancy. Guidelines to improve assessment of appropriateness 250 for most commonly prescribed medications and documents that inform clinical decision-making 251 towards deprescribing, especially those treating comorbidities or prescribed for prevention, are 252 explicitly needed.

Overall, findings suggest pursuing further research on the contribution of clinical guidance towards optimizing drug therapy and deprescribing in inpatient hospice care, rendering drug regimens safe and effective.

256 Acknowledgements

The authors acknowledge the administrators and staff of the *Hospice of Central Switzerland* both for their invaluable collaboration and for introducing us to hospice care. This manuscript was edited for language by Chris Shultis (freelance medical editor).

260 Authors' Contributions

- 261 CMM was responsible for the study concept and the ethics commission proposal. DH collected the
- 262 prescription records, DH and UW analyzed the prescription records. UW performed statistical analyses
- and created the graphs. The manuscript was finalized by UW and CMM. The project was supervised by
- 264 CMM, AK, AP, and CRM; and SJPM contributed her specialist knowledge of hospice care. All authors
- read and approved the final manuscript.

266 Funding information

267 No funding was provided for this study, which was executed within the scope of a master's thesis.

268 Author Disclosure Statement

- 269 One of the authors is employed at the institution where the medication analysis was performed.
- 270 However, there are no conflicts of interest to disclose. All authors declare no competing interests nor
- 271 personal financial interests.

- Watson, M., et al., Oxford Handbook of Palliative Care (Online Access). 3rd ed. Principles of drug use in palliative care (Chapter 5). 2019: Oxford University Press.
- 2. Masman, A.D., et al., *Medication use during end-of-life care in a palliative care centre*. Int J Clin
 276 Pharm, 2015. **37**(5): p. 767-75 DOI: 10.1007/s11096-015-0094-3.
- 277 3. O'Mahony, D. and M.N. O'Connor, *Pharmacotherapy at the end-of-life*. Age Ageing, 2011. 40(4):
 278 p. 419-22 DOI: 10.1093/ageing/afr059.
- 279 4. Rémi, C., et al., *Arzneimitteltherapie in der Palliativmedizin (2nd edition)*. 2015.
- 280 5. Masnoon, N., et al., *What is polypharmacy? A systematic review of definitions*. BMC Geriatr,
 281 2017. 17(1): p. 230 DOI: 10.1186/s12877-017-0621-2.
- Taghy, N., et al., Failure to Reach a Consensus in Polypharmacy Definition: An Obstacle to
 Measuring Risks and Impacts-Results of a Literature Review. Ther Clin Risk Manag, 2020. 16: p.
 57-73 DOI: 10.2147/TCRM.S214187.
- Kotlinska-Lemieszek, A., et al., *Polypharmacy in patients with advanced cancer and pain: a European cross-sectional study of 2282 patients.* J Pain Symptom Manage, 2014. 48(6): p. 1145 DOI: 10.1016/j.jpainsymman.2014.03.008.
- 8. Kadoyama, K.L., et al., *Frequency and Documentation of Medication Decisions on Discharge from*the Hospital to Hospice Care. Journal of the American Geriatrics Society, 2019. 67(6): p. 12581262.
- 2919.Krishnaswami, A., et al., Deprescribing in Older Adults With Cardiovascular Disease. J Am Coll292Cardiol, 2019. **73**(20): p. 2584-2595 DOI: 10.1016/j.jacc.2019.03.467.
- 29310.Frechen, S., et al., Drug interactions in dying patients: a retrospective analysis of hospice294inpatients in Germany. Drug Saf, 2012. **35**(9): p. 745-58 DOI: 10.1007/bf03261971.

- Bauer, D., [Auswirkungen einer intersektoralen pharmakotherapeutischen Betreuung durch
 Apotheker auf die Symptomlast von Palliativpatienten], in Faculty of Medicine (Polyclinic for
 Palliative Medicine). 2018, Ludwig-Maximilian University Munich.
- 298 12. Cruz-Jentoft, A.J., B. Boland, and L. Rexach, *Drug therapy optimization at the end of life.* Drugs
 299 and Aging, 2012. 29(6): p. 511-521.
- Holmes, H.M., *Rational prescribing for patients with a reduced life expectancy*. Clin Pharmacol
 Ther, 2009. 85(1): p. 103-7 DOI: 10.1038/clpt.2008.211.
- 302
 14.
 Currow, D.C., et al., *Prescribing in palliative care as death approaches*. J Am Geriatr Soc, 2007.

 303
 55(4): p. 590-5 DOI: 10.1111/j.1532-5415.2007.01124.x.
- 30415.Akinbolade, O., et al., Deprescribing in advanced illness. Progress in Palliative Care, 2016. 24(5):305p. 268-271 DOI: 10.1080/09699260.2016.1192321.
- 30616.McNeil, M.J., et al., The Burden of Polypharmacy in Patients Near the End of Life. J Pain Symptom307Manage, 2016. **51**(2): p. 178-83 e2 DOI: 10.1016/j.jpainsymman.2015.09.003.
- 30817.Scott, I.A., et al., Reducing inappropriate polypharmacy: the process of deprescribing. JAMA309Intern Med, 2015. 175(5): p. 827-34 DOI: 10.1001/jamainternmed.2015.0324.
- 31018.Morin, L., et al., How many older adults receive drugs of questionable clinical benefit near the311end of life? A cohort study. Palliat Med, 2019.**33**(8): p. 1080-1090 DOI:31210.1177/0269216319854013.
- 313 19. O'Brien, C.P., Withdrawing medication: managing medical comorbidities near the end of life.
 314 Can Fam Physician, 2011. 57(3): p. 304-7, e89-92.
- 31520.Rémi, C., et al., Drug-Related Problems on a Palliative Care Unit. Journal of Pain & Palliative Care316Pharmacotherapy, 2021: p. 1-9 DOI: 10.1080/15360288.2021.1943596.
- 31721.Peralta, T., et al., Prescription trends at the end of life in a palliative care unit: observational318study. BMC Palliat Care, 2022. 21(1): p. 65 DOI: 10.1186/s12904-022-00954-z.
- 31922.Hospiz Zentralschweiz.[cited 2021 August 11]; Available from: https://www.hospiz-320zentralschweiz.ch/
- 32123.ATC/DDD Index 2021. December 17 2020 [cited 2021 April 10]; Available from:322https://www.whocc.no/atc_ddd_index/.
- von Elm, E., et al., *The Strengthening the Reporting of Observational Studies in Epidemiology*(STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol, 2008.
 61(4): p. 344-9 DOI: 10.1016/j.jclinepi.2007.11.008.
- 32625.Agency, E.M.Off-label use.[cited 2022 July 12];Available from:327https://www.ema.europa.eu/en/glossary/label-use.
- Potter, K., et al., *Deprescribing in Frail Older People: A Randomised Controlled Trial.* PLOS ONE,
 2016. 11(3): p. e0149984 DOI: 10.1371/journal.pone.0149984.
- DuMontier, C., et al., Defining Undertreatment and Overtreatment in Older Adults With Cancer:
 A Scoping Literature Review. J Clin Oncol, 2020. 38(22): p. 2558-2569 DOI:
 10.1200/jco.19.02809.
- 28. Lee, J. and M.L. McPherson, *Outcomes of recommendations by hospice pharmacists*. Am J
 334 Health Syst Pharm, 2006. 63(22): p. 2235-9 DOI: 10.2146/ajhp060143.
- Kutner, J.S., et al., Safety and benefit of discontinuing statin therapy in the setting of advanced, *life-limiting illness: a randomized clinical trial.* JAMA Intern Med, 2015. **175**(5): p. 691-700 DOI:
 10.1001/jamainternmed.2015.0289.
- 338 30. Yourman, L.C., et al., Evaluation of Time to Benefit of Statins for the Primary Prevention of
 339 Cardiovascular Events in Adults Aged 50 to 75 Years: A Meta-analysis. JAMA Internal Medicine,
 340 2021. 181(2): p. 179-185 DOI: 10.1001/jamainternmed.2020.6084.
- 341 31. Lenander, C., et al., *Effects of medication reviews on use of potentially inappropriate*342 *medications in elderly patients; a cross-sectional study in Swedish primary care.* BMC Health
 343 Serv Res, 2018. **18**(1): p. 616 DOI: 10.1186/s12913-018-3425-y.
- 344 32. McCarthy, C., et al., *GP-delivered medication review of polypharmacy, deprescribing, and patient priorities in older people with multimorbidity in Irish primary care (SPPiRE Study): A cluster randomised controlled trial.* PLoS Med, 2022. **19**(1): p. e1003862 DOI: 10.1371/journal.pmed.1003862.

- 348 33. Sevilla-Sánchez, D., et al., *Potentially inappropriate medication in palliative care patients*349 *according to STOPP-Frail criteria*. European Geriatric Medicine, 2018. 9(4): p. 543-550 DOI: 10.1007/s41999-018-0073-z.
- 34. Lindsay, J., et al., *The development and evaluation of an oncological palliative care deprescribing guideline: the 'OncPal deprescribing guideline'*. Support Care Cancer, 2015. 23(1): p. 71-8 DOI: 10.1007/s00520-014-2322-0.
- 35435.Le, V., et al., Retrospective analysis of a pilot pharmacist-led hospice deprescribing program355initiative. J Am Geriatr Soc, 2021. 69(5): p. 1370-1376 DOI: 10.1111/jgs.17122.
- 356 36. Pruskowski, J., R. Arnold, and S.J. Skledar, *Development of a health-system palliative care clinical pharmacist*. Am J Health Syst Pharm, 2017. **74**(1): p. e6-e8 DOI: 10.2146/ajhp160055.
- 358 37. Bartz, L., et al., Subcutaneous Administration of Drugs in Palliative Care: Results of a Systematic
 359 Observational Study. Journal of Pain and Symptom Management, 2014. 48(4): p. 540-547 DOI: https://doi.org/10.1016/j.jpainsymman.2013.10.018.
- 36138.Kestenbaum, M.G., et al., Alternative routes to oral opioid administration in palliative care: a362review and clinical summary. Pain Med, 2014. **15**(7): p. 1129-53 DOI: 10.1111/pme.12464.
- 363 39. Dickman, A. and J. Schneider, *The Syringe Driver: Continuous subcutaneous infusions in palliative care.* 4th ed. 2016: Oxford: Oxford University Press.
- 36540.Thomas, T. and S. Barclay, Continuous subcutaneous infusion in palliative care: a review of366current practice. Int J Palliat Nurs, 2015. **21**(2): p. 60, 62-4 DOI: 10.12968/ijpn.2015.21.2.60.
- 367

368 Supplementary Material

369 SA1: Detailed table of patients' baseline data